Cytokinetics (CYTK)

$76.10 +0.23 (0.30%)
Market Cap 9.44B
Revenue (ttm) 88.04M
Net Income (ttm) -784.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -891.59%
Debt to Equity Ratio -1.59
Volume 1,653,000
Avg Vol 2,144,540
Day's Range N/A - N/A
Shares Out 124.43M
Stochastic %K 41%
Beta 0.39
Analysts Strong Sell
Price Target $108.52

Company Profile

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a pot...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 624 3000
Address:
350 Oyster Point Boulevard, South San Francisco, United States
biochirp
biochirp Aug. 14 at 7:01 PM
$CYTK great spot to buy more
0 · Reply
Quantumup
Quantumup Aug. 14 at 11:09 AM
H.C. Wainwright reiterated $CYTK Buy-$140 and said Re: the $BMY litigation: we do not expect it to affect the drug's ongoing commercial momentum, with the product continuing to gain traction following its launch. $EWTX TECX TENX NVO BAYRY Medera - $KVACF Here's what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/2088221120008765890?s=20
0 · Reply
Inarius
Inarius Aug. 13 at 10:34 PM
$CYTK 60s coming
0 · Reply
Quantumup
Quantumup Aug. 13 at 10:33 AM
Barclays⬆️ $CYTK's PT to $110 and said -- With a solid second quarter of sales under Myqorzo's belt and ahead of the full ACACIA data ESC, we take up our forecasts and CYTK price target (from $95 to $110) and reiterate our Overweight rating. $EWTX $BMY TECX TENX Here's what else Barclays had to say: https://x.com/Quantumup1/status/2087849656952738293?s=20
0 · Reply
Zephix
Zephix Aug. 9 at 9:07 PM
$CYTK Bulllish for next week!
1 · Reply
TradingLittlePharma
TradingLittlePharma Aug. 9 at 3:54 PM
$CYTK good earnings, positive sentiment, a current bull trend, and a good pullback to buy in at. This is going up.
0 · Reply
biochirp
biochirp Aug. 7 at 4:24 PM
$CYTK should get bid up when algos are done selling
0 · Reply
buddyopalosam
buddyopalosam Aug. 7 at 1:09 PM
$CYTK dint think there is any catalysts for this to move. Gonna be in the 70/80 range for a while
0 · Reply
Jack_Danielss
Jack_Danielss Aug. 7 at 12:41 PM
$CYTK wen next offering
0 · Reply
Quantumup
Quantumup Aug. 7 at 10:08 AM
Citizens⬆️ $CYTK's PT and said -- Strong MYQORZO launch with continued pipeline development, we reiterate our Market Outperform rating and increase our risk-adjusted, DCF-derived price target to $110 from $105 on Cytokinetics. $EWTX $BMY TENX TECX Citizens added—Yesterday afternoon, Cytokinetics reported 2Q26 financial results with the MYQORZO launches in the U.S. and Europe off to a fast start. Product sales for the quarter were ~$25MM, well ahead of our and consensus estimates. Management commentary on the launch was strong, noting that launch velocity has exceeded expectations. We view the initial launch metrics as compelling support that MYQORZO is both taking share from CAMZYOS and is expanding the CMI market.
0 · Reply
Latest News on CYTK
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 18, 2026, 4:00 PM EDT - 16 hours ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics price target raised to $110 from $95 at Barclays

2026-08-17T08:20:15.000Z - 2 days ago

Cytokinetics price target raised to $110 from $95 at Barclays

Cytokinetics price target raised to $103 from $97 at JPMorgan

2026-08-17T07:59:46.000Z - 2 days ago

Cytokinetics price target raised to $103 from $97 at JPMorgan

Cytokinetics price target raised to $112 from $106 at Truist

2026-08-10T14:15:46.000Z - 8 days ago

Cytokinetics price target raised to $112 from $106 at Truist

Cytokinetics price target raised to $85 from $83 at BofA

2026-08-07T15:50:29.000Z - 11 days ago

Cytokinetics price target raised to $85 from $83 at BofA

Cytokinetics price target raised to $112 from $102 at Needham

2026-08-07T13:38:31.000Z - 11 days ago

Cytokinetics price target raised to $112 from $102 at Needham

Cytokinetics price target lowered to $112 from $117 at RBC Capital

2026-08-07T12:15:42.000Z - 12 days ago

Cytokinetics price target lowered to $112 from $117 at RBC Capital

Cytokinetics price target raised to $110 from $105 at Citizens

2026-08-07T10:17:20.000Z - 12 days ago

Cytokinetics price target raised to $110 from $105 at Citizens

Cytokinetics Earnings Call Transcript: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 12 days ago

Cytokinetics Earnings Call Transcript: Q2 2026

Cytokinetics Earnings release: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 12 days ago

Cytokinetics Earnings release: Q2 2026

Cytokinetics Quarterly report: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 12 days ago

Cytokinetics Quarterly report: Q2 2026

Cytokinetics reports Q2 EPS ($1.50), consensus ($1.60)

2026-08-06T20:06:34.000Z - 12 days ago

Cytokinetics reports Q2 EPS ($1.50), consensus ($1.60)

Cytokinetics wins UK approval, NICE backing for heart disease drug

Jul 30, 2026, 6:48 AM EDT - 20 days ago

Cytokinetics wins UK approval, NICE backing for heart disease drug

Cytokinetics announces MHRA authorization for Myqorzo

2026-07-30T10:25:52.000Z - 20 days ago

Cytokinetics announces MHRA authorization for Myqorzo

Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales

Jul 30, 2026, 6:20 AM EDT - 20 days ago

Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales

Cytokinetics to Announce Second Quarter Results on August 6, 2026

Jul 23, 2026, 4:00 PM EDT - 26 days ago

Cytokinetics to Announce Second Quarter Results on August 6, 2026

Cytokinetics price target lowered to $117 from $119 at RBC Capital

2026-07-07T11:36:10.000Z - 6 weeks ago

Cytokinetics price target lowered to $117 from $119 at RBC Capital

Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026

Jul 7, 2026, 7:30 AM EDT - 6 weeks ago

Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026

Cytokinetics upgraded to Buy from Neutral at UBS

2026-06-29T10:20:13.000Z - 7 weeks ago

Cytokinetics upgraded to Buy from Neutral at UBS

Cytokinetics price target raised to $118 from $100 at Mizuho

2026-06-24T11:06:08.000Z - 2 months ago

Cytokinetics price target raised to $118 from $100 at Mizuho

Cytokinetics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 9:20 AM EDT - 2 months ago

Cytokinetics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program

Jun 8, 2026, 7:30 AM EDT - 2 months ago

Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program

Cytokinetics Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 8:10 AM EDT - 2 months ago

Cytokinetics Transcript: Jefferies Global Healthcare Conference 2026

Cytokinetics launches Myqorzo in Germany

2026-06-01T14:24:49.000Z - 2 months ago

Cytokinetics launches Myqorzo in Germany

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

Jun 1, 2026, 7:30 AM EDT - 2 months ago

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

Cytokinetics to Participate in June Investor Conferences

May 27, 2026, 4:00 PM EDT - 2 months ago

Cytokinetics to Participate in June Investor Conferences

Cytokinetics Transcript: AGM 2026

May 27, 2026, 1:00 PM EDT - 2 months ago

Cytokinetics Transcript: AGM 2026

Cytokinetics Slides: Corporate presentation

May 27, 2026, 7:00 AM EDT - 3 months ago

Cytokinetics Slides: Corporate presentation

Cytokinetics to Hold Annual Meeting of Stockholders

May 20, 2026, 4:00 PM EDT - 3 months ago

Cytokinetics to Hold Annual Meeting of Stockholders

Cytokinetics Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 3:35 PM EDT - 3 months ago

Cytokinetics Transcript: RBC Capital Markets Global Healthcare Conference 2026

Cytokinetics Slides: Corporate presentation

May 19, 2026, 7:00 AM EDT - 3 months ago

Cytokinetics Slides: Corporate presentation

Cytokinetics initiated with a Buy, named a top pick at Citi

2026-05-18T20:22:58.000Z - 3 months ago

Cytokinetics initiated with a Buy, named a top pick at Citi

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

May 18, 2026, 4:00 PM EDT - 3 months ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

C

Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)

May 14, 2026, 7:30 AM EDT - 3 months ago

Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)

Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

May 12, 2026, 4:00 PM EDT - 3 months ago

Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Cytokinetics price target raised to $97 from $92 at JPMorgan

2026-05-12T12:21:58.000Z - 3 months ago

Cytokinetics price target raised to $97 from $92 at JPMorgan

Cytokinetics announces new data related to Myqorzo at ESC Heart Failure 2026

2026-05-11T19:30:39.000Z - 3 months ago

Cytokinetics announces new data related to Myqorzo at ESC Heart Failure 2026

Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026

May 11, 2026, 10:06 AM EDT - 3 months ago

Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026

Cytokinetics price target raised to $140 from $136 at H.C. Wainwright

2026-05-11T10:26:13.000Z - 3 months ago

Cytokinetics price target raised to $140 from $136 at H.C. Wainwright

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million

May 8, 2026, 10:51 AM EDT - 3 months ago

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

May 6, 2026, 11:00 PM EDT - 3 months ago

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

Cytokinetics Earnings Call Transcript: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Cytokinetics Earnings Call Transcript: Q1 2026

Cytokinetics Quarterly report: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Cytokinetics Quarterly report: Q1 2026

Cytokinetics Earnings release: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Cytokinetics Earnings release: Q1 2026

Cytokinetics Slides: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Cytokinetics Slides: Q1 2026

Cytokinetics Announces Proposed Public Offering of Common Stock

May 5, 2026, 4:15 PM EDT - 3 months ago

Cytokinetics Announces Proposed Public Offering of Common Stock

Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update

May 5, 2026, 4:05 PM EDT - 3 months ago

Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update

Cytokinetics Transcript: Study result

May 5, 2026, 8:00 AM EDT - 3 months ago

Cytokinetics Transcript: Study result

Cytokinetics Press release: Study result

May 5, 2026, 8:00 AM EDT - 3 months ago

Cytokinetics Press release: Study result

Cytokinetics Slides: Study result

May 5, 2026, 8:00 AM EDT - 3 months ago

Cytokinetics Slides: Study result

Cytokinetics heart disease drug meets main goals in late-stage study

May 5, 2026, 7:35 AM EDT - 3 months ago

Cytokinetics heart disease drug meets main goals in late-stage study

Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy

May 5, 2026, 7:30 AM EDT - 3 months ago

Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy

Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026

May 4, 2026, 4:00 PM EDT - 3 months ago

Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026

Cytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress

Apr 28, 2026, 7:30 AM EDT - 4 months ago

Cytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress

Cytokinetics to Announce First Quarter Results on May 5, 2026

Apr 21, 2026, 4:00 PM EDT - 4 months ago

Cytokinetics to Announce First Quarter Results on May 5, 2026

Cytokinetics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Cytokinetics Proxy statement: Proxy filing

Cytokinetics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 13, 2026, 1:30 PM EDT - 4 months ago

Cytokinetics Transcript: 25th Annual Needham Virtual Healthcare Conference

Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference

Apr 6, 2026, 4:00 PM EDT - 4 months ago

Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference

Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo

Mar 16, 2026, 8:00 AM EDT - 5 months ago

Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo

Cytokinetics Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 11, 2026, 12:30 PM EDT - 5 months ago

Cytokinetics Transcript: Barclays 28th Annual Global Healthcare Conference

Cytokinetics Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 9:00 AM EDT - 5 months ago

Cytokinetics Transcript: The Citizens Life Sciences Conference 2026

Cytokinetics Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 9:20 AM EDT - 5 months ago

Cytokinetics Transcript: Leerink Global Healthcare Conference 2026

Cytokinetics Slides: Corporate presentation

Mar 5, 2026, 7:00 AM EST - 5 months ago

Cytokinetics Slides: Corporate presentation

Cytokinetics to Participate in March Investor Conferences

Mar 2, 2026, 4:00 PM EST - 6 months ago

Cytokinetics to Participate in March Investor Conferences

Cytokinetics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 4:30 PM EST - 6 months ago

Cytokinetics Earnings Call Transcript: Q4 2025

Cytokinetics Annual report: Q4 2025

Feb 24, 2026, 4:30 PM EST - 6 months ago

Cytokinetics Annual report: Q4 2025

Cytokinetics Earnings release: Q4 2025

Feb 24, 2026, 4:30 PM EST - 6 months ago

Cytokinetics Earnings release: Q4 2025

Cytokinetics Annual report: Q4 2025

Feb 24, 2026, 4:30 PM EST - 6 months ago

Cytokinetics Annual report: Q4 2025

Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update

Feb 24, 2026, 4:00 PM EST - 6 months ago

Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update

Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Feb 17, 2026, 7:30 AM EST - 6 months ago

Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Cytokinetics to Announce Fourth Quarter Results on February 24, 2026

Feb 12, 2026, 4:00 PM EST - 6 months ago

Cytokinetics to Announce Fourth Quarter Results on February 24, 2026

Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program

Feb 9, 2026, 7:30 AM EST - 6 months ago

Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program

Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Jan 27, 2026, 7:30 AM EST - 7 months ago

Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors

Jan 22, 2026, 2:39 PM EST - 7 months ago

The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors

Cytokinetics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 12:45 PM EST - 7 months ago

Cytokinetics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Cytokinetics Slides: Corporate presentation

Jan 12, 2026, 7:00 AM EST - 7 months ago

Cytokinetics Slides: Corporate presentation

Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 4:00 PM EST - 8 months ago

Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Cytokinetics Transcript: FDA Announcement

Dec 19, 2025, 4:30 PM EST - 8 months ago

Cytokinetics Transcript: FDA Announcement

Cytokinetics Press release: FDA Announcement

Dec 19, 2025, 4:30 PM EST - 8 months ago

Cytokinetics Press release: FDA Announcement

US FDA approves Cytokinetics' heart disease drug

Dec 19, 2025, 4:08 PM EST - 8 months ago

US FDA approves Cytokinetics' heart disease drug

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Dec 19, 2025, 4:00 PM EST - 8 months ago

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy

Dec 17, 2025, 7:30 AM EST - 8 months ago

Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Dec 12, 2025, 8:42 AM EST - 8 months ago

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Cytokinetics Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 9:30 AM EST - 9 months ago

Cytokinetics Transcript: Jefferies London Healthcare Conference 2025

Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy

Nov 17, 2025, 8:10 AM EST - 9 months ago

Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy

Cytokinetics Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 11:20 AM EST - 10 months ago

Cytokinetics Transcript: Stifel 2025 Healthcare Conference

Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

Nov 10, 2025, 7:30 AM EST - 10 months ago

Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

biochirp
biochirp Aug. 14 at 7:01 PM
$CYTK great spot to buy more
0 · Reply
Quantumup
Quantumup Aug. 14 at 11:09 AM
H.C. Wainwright reiterated $CYTK Buy-$140 and said Re: the $BMY litigation: we do not expect it to affect the drug's ongoing commercial momentum, with the product continuing to gain traction following its launch. $EWTX TECX TENX NVO BAYRY Medera - $KVACF Here's what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/2088221120008765890?s=20
0 · Reply
Inarius
Inarius Aug. 13 at 10:34 PM
$CYTK 60s coming
0 · Reply
Quantumup
Quantumup Aug. 13 at 10:33 AM
Barclays⬆️ $CYTK's PT to $110 and said -- With a solid second quarter of sales under Myqorzo's belt and ahead of the full ACACIA data ESC, we take up our forecasts and CYTK price target (from $95 to $110) and reiterate our Overweight rating. $EWTX $BMY TECX TENX Here's what else Barclays had to say: https://x.com/Quantumup1/status/2087849656952738293?s=20
0 · Reply
Zephix
Zephix Aug. 9 at 9:07 PM
$CYTK Bulllish for next week!
1 · Reply
TradingLittlePharma
TradingLittlePharma Aug. 9 at 3:54 PM
$CYTK good earnings, positive sentiment, a current bull trend, and a good pullback to buy in at. This is going up.
0 · Reply
biochirp
biochirp Aug. 7 at 4:24 PM
$CYTK should get bid up when algos are done selling
0 · Reply
buddyopalosam
buddyopalosam Aug. 7 at 1:09 PM
$CYTK dint think there is any catalysts for this to move. Gonna be in the 70/80 range for a while
0 · Reply
Jack_Danielss
Jack_Danielss Aug. 7 at 12:41 PM
$CYTK wen next offering
0 · Reply
Quantumup
Quantumup Aug. 7 at 10:08 AM
Citizens⬆️ $CYTK's PT and said -- Strong MYQORZO launch with continued pipeline development, we reiterate our Market Outperform rating and increase our risk-adjusted, DCF-derived price target to $110 from $105 on Cytokinetics. $EWTX $BMY TENX TECX Citizens added—Yesterday afternoon, Cytokinetics reported 2Q26 financial results with the MYQORZO launches in the U.S. and Europe off to a fast start. Product sales for the quarter were ~$25MM, well ahead of our and consensus estimates. Management commentary on the launch was strong, noting that launch velocity has exceeded expectations. We view the initial launch metrics as compelling support that MYQORZO is both taking share from CAMZYOS and is expanding the CMI market.
0 · Reply
Florestan
Florestan Aug. 7 at 9:37 AM
$CYTK 100+ by eoy.
0 · Reply
Daniech0514
Daniech0514 Aug. 6 at 10:04 PM
$CYTK good acceleration of prescriptions and the start of expansion into European markets. I know some people may be upset with them not taking a buyout. But IMO much brighter days ahead and still maybe a buyout bu at higher levels.
2 · Reply
Golfpimp4017
Golfpimp4017 Aug. 6 at 9:04 PM
$CYTK well AMD worked on my timeline. Also, if you’ve been invested in this and set out the last two years, your opportunity cost is outrageous!!
1 · Reply
forprofit12
forprofit12 Aug. 6 at 9:02 PM
$CYTK what a fucking moron. Just because the stock is not performing based on your own set timeline it is trash? Why don’t you ask any AI service if cytk is trash.
0 · Reply
LewisDaKat
LewisDaKat Aug. 6 at 9:00 PM
$CYTK Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update https://marketwirenews.com/stock/cytk/news/cytokinetics-reports-second-quarter-2026-financial-r-6769143781672781.html?utm_source=stocktwits
0 · Reply
Merlintrader
Merlintrader Aug. 6 at 8:38 PM
Cytokinetics ($CYTK) Stock Hub 2026: MYQORZO, Aficamten and the Hypertrophic Cardiomyopathy Franchise Expansion https://www.merlintrader.com/cytokinetics-incorporated-stock-hub/
0 · Reply
Golfpimp4017
Golfpimp4017 Aug. 6 at 8:37 PM
$CYTK well no Princess it’s a fact. Clearly your concerned more about my opinion then your fly by night garbage stock. https://endpoints.news/cytokinetics-ceo-addresses-acquisition-rumors-says-buyer-walked-away-sec-filing-shows/
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 6 at 8:27 PM
$CYTK Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$1.50 down -33.93% YoY • Reported revenue of $28.62M down -57.13% YoY • Cytokinetics is updating its full year 2026 financial guidance for GAAP combined R&D and SG&A expense to $860 million to $890 million, including $140 million to $130 million of stock-based compensation.
0 · Reply
Golfpimp4017
Golfpimp4017 Aug. 6 at 8:15 PM
$CYTK it’s rare I will trash a company but this one is garbage. The C-suite has already made a fortune selling companies. They don’t care about selling this. They turned down 120 a share and that was YEARS ago. There stock has never sniffed that price!!! Expect the day they thought it may happen.
1 · Reply
Golfpimp4017
Golfpimp4017 Aug. 6 at 8:11 PM
$CYTK garbage. There never selling.
0 · Reply
Bizzonaci
Bizzonaci Aug. 6 at 6:27 PM
$CYTK my biggest bio position by far not even planning on hedging here will add more after report
0 · Reply
Daniech0514
Daniech0514 Aug. 6 at 1:07 AM
$CYTK less than 24 hrs. From earnings can't wait to see how prescriptions grew to see how much blockbuster potential this has. Last q numbers> 680 unique patients prescribed Mycorzo ...by 275 different HCPs.
0 · Reply